Drug Trial Radar · NCT03298451
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,324
Actual
Start
Oct 11, 2017
Primary completion
Aug 27, 2021
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC. The patients cannot be eligible for locoregional therapy
Conditions
- Hepatocellular Carcinoma
Interventions
DurvalumabDrug
Durvalumab IV (intravenous infusion).
Tremelimumab (Regimen 1)Drug
Tremelimumab IV (intravenous infusion).
Tremelimumab (Regimen 2)Drug
Tremelimumab IV (intravenous infusion).
SorafenibDrug
Sorafenib, as per standard of care
Durvalumab (Regimen 1)Drug
Durvalumab IV (intravenous infusion).
Durvalumab (Regimen 2)Drug
Durvalumab IV (intravenous infusion).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mgTime frame: From the date of randomization until death due to any cause, assessed up to the data cut-off date (27Aug2021, to a maximum of approximately 46 months).
Locations
160 sites in 17 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California
Research Site
Orange, California
Research Site
San Francisco, California
Research Site
Washington D.C., District of Columbia
Research Site
Fort Myers, Florida
Research Site
Jacksonville, Florida
Research Site
Westwood, Kansas
Research Site
Baltimore, Maryland
Research Site
Ann Arbor, Michigan
Research Site
Rochester, Minnesota
Research Site
New York, New York
Research Site
Charlotte, North Carolina
Research Site
Portland, Oregon
Research Site
Pittsburgh, Pennsylvania
Research Site
Dallas, Texas
Research Site
Dallas, Texas
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
Houston, Texas
Research Site
Murray, Utah
Research Site
Barretos, Brazil
Research Site
Curitiba, Brazil
Research Site
Florianópolis, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
São Paulo, Brazil
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Kingston, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Sherbrooke, Quebec, Canada
Research Site
Beijing, China
Research Site
Changchun, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Dalian, China
Showing 40 of 160 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.